Search Results - Therapeutics > Small Molecule

7 Results Sort By:
Novel Capsazepine Analogs to Treat Cancer
Novel compounds have been developed based upon the capsazepine pharmacophore that are effective in halting tumor cell proliferation in vitro and in vivo. Capsazepine is a known, off-patent, analog of Capsaicin that has been proposed and studied as a TRPV1 antagonist for treatment of pain. Although Capsazepine has been proposed for alleviation of p...
Published: 8/23/2018   |   Inventor(s): Cara Gonzales, Stanton McHardy
Keywords(s):  
Category(s): Clinical Specialty > Oncology, Therapeutics > Small Molecule
Novel Compounds to Inhibit Cancer, Cancer Metastasis, and Autoimmune Diseases
Several candidate small molecules have been discovered that show dose-dependent anti-cancer effects in vitro. These compounds each have one of the following characteristics: (1) non-hydrolyzable ATP analog or (2) adenosine receptor antagonist. Testing of these compounds has demonstrated successful inhibition of cancer cell migration. Additionally...
Published: 5/22/2018   |   Inventor(s): Jean Jiang
Keywords(s):  
Category(s): Clinical Specialty > Immunology, Clinical Specialty > Oncology, Therapeutics > Small Molecule
Intravenous Tramadol for Treatment of anti-NMDA Encephalitis
The invention is a combinatorial therapy used to enhance the efficacy of plasma exchange (PLEX) in treating patients with anti-NMDAR encephalitis. This treatment regimen would treat both the psychiatric and immunological manifestations of this disorder and substantially lower the patients’ recovery periods. Background:Anti-NMDAR encephalitis ...
Published: 4/20/2018   |   Inventor(s): Ali Seifi
Keywords(s):  
Category(s): Therapeutics > Small Molecule, Clinical Specialty > Neurology, Clinical Specialty > Oncology, Clinical Specialty > Immunology
Combination of DHA and HDACIs in treating Prostate Cancer
The disclosed invention is a proposed combination therapy to treat prostate cancer, especially prostate cancer patients with biochemical recurrence (BCR). The combination therapy is composed of UTH1, a fatty acid compound with Generally Recognized As Safe (GRAS) status, and Valproic Acid (VPA), a generic drug with clinical use since 1963 as a mood ...
Published: 3/9/2018   |   Inventor(s): Wasim Chowdhury, Ronald Rodriguez, Md Rahman
Keywords(s):  
Category(s): Therapeutics > Small Molecule, Clinical Specialty > Oncology, Clinical Specialty > Reproductive Health, Clinical Specialty > Urology
Allosteric Proteasome Inhibitors for Treatment of Cancer
UT Health San Antonio scientists have discovered novel small-molecule compounds that have allosteric signaling activity to modulate proteasome catalytic activity. The allosteric proteasome inhibitors can be used alone or in combination with existing competitive proteasome inhibitors for the treatment of cancer. Studies of combination treatment de...
Published: 4/10/2015   |   Inventor(s): Pawel Osmulski, Maria Gaczynska
Keywords(s):  
Category(s): Therapeutics > Small Molecule, Clinical Specialty > Oncology
Novel Inhibitors of Proto-Oncogene PELP1
Novel peptide inhibitors that disrupts the functional interactions of oncogenic protein PELP1 have been discovered by researchers at UT Health San Antonio. These inhibitors can be used for treatment of cancers that are characterized as over-expressing PELP1.Background:PELP1 overexpression, noted in many hormone-related cancers such as breast, prost...
Published: 4/10/2015   |   Inventor(s): Ratna Vadlamudi, Monica Mann, Samaya Krishnan, Gangadhara Sareddy
Keywords(s):  
Category(s): Therapeutics > Small Molecule, Clinical Specialty > Oncology
Salvinia Cyctotoxic Compounds for Treatment of Cancer
Novel plant-derived compounds that have cytotoxic properties against cancer cells and therefore may be potent anticancer therapeutics have been discovered by UT Health San Antonio researchers. These compounds are derived from giant salvinia, one of the most noxious invasive species of plants in the world. The compounds showed selective cytotoxic ac...
Published: 4/23/2013   |   Inventor(s): Shiyou Li, Ping Wang, Guangrui Deng, Wei Yuan, Zushang Su
Keywords(s): Drugs
Category(s): Therapeutics > Small Molecule, Clinical Specialty > Oncology